Selective Investment 2000 Award Recipients
Already the national leader in the use of robotics surgery and renowned for research in microdevices that could be used for drug delivery (nanotechnology), Ohio State expects to become a world leader in biomedical engineering by combining the expertise of engineers and clinicians to find innovative ways to diagnose and treat heart disease.
all split appointments, are proposed over four years to complement the
current faculty and researchers specializing in these
Researchers envision advances in the development
of metal alloys
and drug-delivery systems that will increase effectiveness of treatment
and reduce p atient
side effects in the fight against the leading cause of death in the United
"The people we hire are going to be living and breathing more than one discipline," said Robert Michler, chief of cardiothoracic surgery, co-director of the Heart and Lung Research Institute, and the Karl P. Klassen professor of surgery. "As a result of that, the natural kinds of collaborations that you want to occur will occur. We'll see some world-class events happening right here at Ohio State."
Mauro Ferrari, director of the Biomedical Engineering Center and associate director of the Heart and Lung Research Institute, said the Selective Investment proposal was designed to position Ohio State as home to a top U.S. biomedical engineering program. "We expect to attain leadership by focusing on classes of diseases," said Ferrari, also professor of internal medicine, mechanical engineering and materials science. "We are starting with cardiology, and plan to follow up in the areas of oncology and endocrinology."